MBZUAI valedictorian Salma Hassan developed a multimodal graph learning approach for early dementia diagnosis and prognosis. Her master's thesis focused on differential diagnosis to identify specific dementia subtypes and predicting cognitive decline in preclinical patients. The AI model leverages brain imaging, genetics, and clinical records to improve diagnostic accuracy. Why it matters: This research can improve early detection and resource allocation for dementia management, especially in developing countries.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
A senior lecturer at the University of New South Wales discussed the use of AI to improve early prognosis and personalized treatment plans for neurodegenerative diseases, cardiovascular imaging and multiomics. The lecture highlighted the potential of AI algorithms to detect subtle changes at early stages through advanced multiomics techniques and medical imaging analysis. The speaker has expertise in analyzing medical images and has collaborated with medical professionals to develop AI tools for diagnosis of cancer, neurodegenerative disease, and heart disease. Why it matters: AI-driven prognosis and treatment planning promises earlier intervention and improved outcomes for challenging diseases in the region.
MBZUAI researchers developed Human-in-the-Loop for Prognosis (HuLP), a new AI system designed to help physicians assess cancer progression by providing information about its predictions and allowing user intervention. The system aims to foster collaboration between physicians and AI, rather than replacing doctors. It was presented at the 27th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI). Why it matters: This research highlights the potential of AI to augment physician expertise in critical areas like cancer prognosis, improving patient care and treatment decisions.
Researchers at MBZUAI have developed a new machine learning method called survival rank-n-contrast (SurvRNC) to improve survival models for cancer prognoses. The method is designed to predict survival times for head and neck cancer patients using multimodal data while accounting for censored data (missing values). Numan Saeed presented the team’s work at the 27th International Conference on Medical Image Computing and Computer Assisted Intervention (MICCAI). Why it matters: Accurate prognoses can significantly improve patient outcomes, and this research contributes to advancements in machine learning techniques for handling complex and incomplete medical data.
MBZUAI's first Ph.D. graduate, Numan Saeed, developed deep learning models to diagnose head and neck cancers using PET and CT scan imagery. His research focused on improving early detection and accurate localization of tumors, aiming to enhance diagnosis and prognosis. Early diagnosis can reduce mortality rates by up to 70%. Why it matters: This research showcases the potential of AI in healthcare to improve cancer diagnosis and treatment, addressing a critical need in resource-constrained healthcare systems.
MBZUAI awarded its first Ph.D. to Numan Saeed for his dissertation, "Deep Learning for Cancer Diagnosis and Prognosis." Saeed's research explores using deep learning models to diagnose tumors and predict survival rates for head and neck cancers by interpreting PET and CT scan imagery and doctor's notes. The AI model considers variables like age, gender, and tumor size to improve diagnosis, especially in regions with limited oncological services. Why it matters: This milestone highlights MBZUAI's growing role in AI research and its potential to contribute to advancements in AI-driven healthcare solutions, particularly for cancer diagnosis and treatment.